بهترین پادکست های Labiotech (2024)

1
Could antigen modulation address autoimmune diseases? 24:04

15h ago24:04

24:04

Immunology is a key area in biotech and biopharma, both in terms of R&D and sales. However, according to UK-headquartered Grey Wolf Therapeutics, the industry has only focused on two-thirds of the puzzle. To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. The first is antigen re…

1
Beyond profits: The Bill & Melinda Gates MRI's mission to combat neglected diseases 38:10

8d ago38:10

38:10

The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantial global health concerns, for which investment incentives are limited, including malaria, tuberculosis, diarrheal…

1
How to succeed as a woman in biotech 34:12

15d ago34:12

34:12

This week, we are taking a look at an important subject, and that is women working as CEOs, or other senior roles, in the biotech space. Kate Yen is the CEO of oncology biotech Auron Therapeutics, and she has spent her entire career in science. Auron is working on the next generation of targeted cancer therapies by identifying and inhibiting the on…

1
The immunometabolism landscape 30:13

22d ago30:13

30:13

Sitryx Therapeutics is a private UK biopharma company founded in 2018. It is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sustained disease remission in autoimmune and inflammatory diseases. Sitryx already has big pharma validation following a deal with Eli Lilly in 2020 worth…

1
Biotech beyond earth: The future of medicine in space 39:01

29d ago39:01

39:01

LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease. Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an article about how space-travel is especially damaging to the kidneys, they applied for a place on the inaugural N…

1
The future of gene therapy 33:25

1M ago33:25

33:25

Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent diseases. Spur Therapeutics is a clinical-stage biotech company dedicated to developing next genera…

1
Bispecific ADCs: the next generation of cancer treatments 29:45

1M ago29:45

29:45

Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-site toxicity has remained a challenge. Some biopharma companies are investing in what they hope will be the next-generation approach to ADCs – bispecific…

1
Targeting telomerase to disrupt cancer 26:30

2M ago26:30

26:30

Telomeres are structures made from DNA sequences and proteins, and they are found at the ends of chromosomes. In effect, they cap and protect the end of a chromosome. Telomerase is an enzyme that adds DNA to the ends of chromosomes, and it is reactivated in most cancers. Most human tumors not only express telomerase but also have very short telomer…

1
Harnessing the body’s natural targeted protein degradation system to treat diseases 34:04

2M ago34:04

34:04

C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. The clinical-stage biopharmaceutical company is dedicated to creating a new generation of medicines using its TORPEDO platform to des…

1
Estonia's biobank: Is this the first large-scale personalized medicine initiative? 32:15

2M ago32:15

32:15

Estonia is working on becoming the first country to implement personalized health at scale through the Estonian National Biobank. The biobank uses genetic data to create a picture of the Estonian population, leading to the potential adaptation of public health systems. The Estonian Biobank has samples from 20% of the adult population; in comparison…

1
Targeting inflammation: A revolution in disease treatment 43:10

2M ago43:10

43:10

Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders. NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies including fibrotic, dermatological, rheumatological diseases as well as neurological disorders such as Alz…

1
The power of tumor infiltrating lymphocytes to fight melanoma 38:03

3M ago38:03

38:03

Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. This week, we have a conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline. Iovance recently submitted a marke…

1
The future of combination vaccines 24:44

3M ago24:44

24:44

The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly improve public health preparedness. Moderna is harnessing the power of its mRNA platform to develop vaccines…

1
New German biotech spins out to develop radiotherapeutics 18:35

3M ago18:35

18:35

Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separate company. Pentixapharm’s clinical pipeline includes PENTIXATHER, am Yttrium-90 based therapeutic against CNS lymphoma, and PENTIXAFOR, a Gallium-68 b…

1
Challenging the European biotech funding status quo 36:36

3M ago36:36

36:36

There are many questions when it comes to setting up a biotech company, and raising funds. Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. Does a company’s location affect fundraising? What is the best approach to successfully raise funds? What are the current trends in biotech f…

1
[Rebroadcast] Epigenetic editing – the power of CRISPR without cutting DNA 32:57

4M ago32:57

32:57

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer! Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) inc…

1
[Rebroadcast] How does AI assist drug discovery? 38:40

4M ago38:40

38:40

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer! Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time. A new collaboration between artificial int…

1
The first mass-market cell therapy? 25:34

4M ago25:34

25:34

Aurion Biotech is a US biotech with a regenerative medicine platform, developing novel therapies to restore vision to millions of people in need. This week on the podcast, we have a conversation with CEO Greg Kunst about Aurion’s pipeline, and how the company’s treatment could be the first mass-market cell therapy available. The FDA has granted the…

1
Cutting through the AI hype in drug discovery 26:13

4M ago26:13

26:13

LabGenius is a drug discovery company developing next-generation therapeutic antibodies. The company’s discovery platform, EVA, integrates several technologies drawn from the fields of artificial intelligence (AI), robotic automation and synthetic biology. LabGenius operates under a hybrid business model that involves partnering with large biotech …

1
How biotechs are revolutionizing acute on-chronic liver failure? 29:22

4M ago29:22

29:22

Acute on-chronic liver failure (ACLF) is a significant healthcare issue with high unmet needs for patients and clinicians, and a massive burden for healthcare systems. It cost more than $6bn in the US alone in 2021, with a drastic increase over the last 10 years. Genfit is a late-stage biopharma company taking on rare, life-threatening liver diseas…

1
The radiotherapeutics boom 39:43

5M ago39:43

39:43

The field of radiotherapeutics is a hot topic currently, and so who better to talk about the subject than Ken Herrmann, a radiopharmaceutical academic expert, who is Professor of Nuclear Medicine at the Universitätsklinikum Essen, in Essen Germany, and two people from the company Molecular Partners: Patrick Amstutz, who is a co-founder and the CEO,…

1
Priovant - finding options to treat autoimmune diseases 30:05

5M ago30:05

30:05

US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses key cytokines linked to autoimmu…

1
How ADCs can deliver death cap mushroom toxins to treat cancer 28:09

5M ago28:09

28:09

Heidelberg Pharma is a clinical stage biotech company developing antibody drug conjugates (ADCs). Its lead amanitin-based ADC product candidate, HDP-101, targets relapsed or refractory multiple myeloma. HDP-101 recently received orphan drug designation; it is currently in a phase I/IIa clinical trial, demonstrating first signs of clinical efficacy.…

1
Looking to cure Type 1 diabetes 23:40

5M ago23:40

23:40

Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. It has been granted Orphan Drug Designation in the U.S. as well as Fast Track Desi…

1
Developing treatments for rare pediatric diseases 29:17

6M ago29:17

29:17

Rare diseases affect around 1 in 2,000 people. Many of the thousands of rare diseases are difficult to diagnose. Of the known rare diseases, about 80% have genetic causes. Leukodystrophies are a group of rare genetic disorders for which there is currently no curative therapy. This week on the podcast we are discussing novel treatments of rare pedia…

1
Can cell therapy tackle hearing loss? 31:00

6M ago31:00

31:00

Hearing loss is a huge – and growing – global challenge. Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant global medical challenge. The company’s lead asset, Rincell-1, is designed to regenerate auditory neurons a…

1
How biotech is tackling myasthenia gravis 28:50

6M ago28:50

28:50

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles. It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and…

1
Antisense oligonucleotides 27:22

6M ago27:22

27:22

German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications…

1
Making waves in cardiovascular disease treatment 21:02

7M ago21:02

21:02

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. This week, we have a conversation with the …

1
New ways to treat Duchenne muscular dystrophy 23:56

7M ago23:56

23:56

Duchenne muscular dystrophy (DMD) is a genetic disorder with progressive muscle degeneration and weakness due to changes in the protein dystrophin, which helps keep muscle cells intact. There are few treatments for DMD, although recent advances mean that males – who are primarily affected by DMD – can now sometimes survive into their 30s. More drug…

1
Overcoming clinical trial challenges 26:00

7M ago26:00

26:00

This week, we have a conversation about clinical trial design with Gen Li, the president and founder of Phesi, a global provider of patient-centric data analysis. Earlier this year, Phesi’s global analysis of all clinical trials conducted in 2023 revealed that more than a quarter (28%) of trials were cancelled during phase II – above the average at…

1
The biotech investment landscape in 2024 28:32

7M ago28:32

28:32

RTW is a global multi-strategy investment firm focused on supporting innovative biotech and biopharma companies across the US, Europe, and China. The company invests in both public and private companies across their entire life cycle, with a focus on those addressing next-generation gene and RNA therapies, rare diseases, targeted oncological, cardi…

1
Redefining chronic pain treatment 35:42

7M ago35:42

35:42

Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcriptomic technologies or proteomic technologies to better understand the progression of neurological diseases like chronic pain. The Doloromics pipeline is…

1
Colossal aims to bring back mammoth by 2028 38:24

8M ago38:24

38:24

Based in Austin, Texas, biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems. Its mission is to use CRISPR technology to bring back extinct animals, such as the mammoth, the thylacine, and the dodo. Since DNA was recovered in 2021 from mammoths frozen…

1
New treatments being developed for schizophrenia 25:31

8M ago25:31

25:31

It would appear that 2024 is shaping up to be a big year for the development of treatments for schizophrenia, with several clinical trials under way. Recently, Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) announced a global collaboration and exclusive option-to-license agreement. This is to develop and commercialize Sosei Hepta…

1
Reformulating psychedelics for neurodegenerative diseases 41:37

8M ago41:37

41:37

There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient. Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics …

1
How AI immune system mapping can boost drug discovery 28:46

9M ago28:46

28:46

Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. The ultimate goal is to market immune treatments for diseases like cancer faster than ever before. In this wee…

1
Is Tome writing the final chapter in genomic medicine? 33:11

9M ago33:11

33:11

Tome Biosciences recently exited stealth mode with almost a quarter of a billion dollars in funding. The company has developed a new approach to gene editing, programmable genomic integration (PGI), which it says represents the final chapter in genomic medicines. We discussed the company’s formation and approach with the CEO and president of Tome, …

1
Transforming treatments for epilepsy 41:27

9M ago41:27

41:27

After decades of lagging nearly many other disease areas, neurology is finally seeing signs of significant innovation. One of the biggest reasons it’s trailed behind has been the difficulty in teasing out complex neurobiology – an understanding necessary to design novel medicines. Rapport Therapeutics is playing a significant role in turning the ti…

1
How does AI assist drug discovery? 38:26

9M ago38:26

38:26

Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time. A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" canc…

1
Biosimilars and what’s new in cell and gene therapies 37:17

10M ago37:17

37:17

This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health. The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and what’s new at Advanced Therapies Week. 00:40-02:30: About Cardinal Health 02:30-05:12: What is Cardinal Health’s …

1
BioSenic developing severe knee osteoarthritis treatment 31:43

10M ago31:43

31:43

BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria. The post hoc analysis of a phase 3 study found that a single injection of JT…

1
Boosting fertility by changing the vaginal microbiome 32:38

10M ago32:38

32:38

Freya Biosciences is a clinical-stage biotech company dedicated to reimagining women's health and redefining fertility for those previously deprived of options. With a focus on microbial immunotherapies, Freya addresses immune drivers underlying a range of reproductive health conditions. The company recently received $38 million Series A financing …

1
Epic Bio - gene editing without cutting DNA 32:43

10M ago32:43

32:43

Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. This week, we discuss epigenetic editing, why it’s reversibl…

1
Could natural killer cells transform Alzheimer’s treatment? 28:14

11M ago28:14

28:14

A US company, with its origins in South Korea, is using natural killer (NK) cells to treat Alzheimer’s disease, with remarkable results. This week, we have a conversation with Dr Paul Song, CEO of NKGen Biotech, a company with its sights set on changing the Alzheimer’s treatment landscape. 00:58-02:55: About NKGen Biotech 02:56-05:39: Why is Alzhei…

1
Gene editing in the microbiome to treat acne 29:02

11M ago29:02

29:02

Eligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome. Its first target is moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population. This week, we talk to Xavier Duportet, CEO of Eligo Bioscience, as the company looks …

1
Tackling challenging diseases with vaccines 25:47

11M ago25:47

25:47

Vaxxinity, Inc. is a U.S.-based biotechnology company looking to develop vaccines for several hard-to-treat diseases such as Alzheimer’s and Parkinson’s. The company is pioneering a new class of medicines through its proprietary technology platform, which has enabled the innovation of novel synthetic peptide immunotherapy candidates to bring the ef…

1
Using worms to treat diseases 21:37

12M ago21:37

21:37

Is there a connection between worms being eradicated from the gut in the early 20th Century and an increase in allergies and autoimmune disease? This week, we have a conversation with Holoclara CEO Andrea Choe, who not only believes there is a connection, but also sees secretions from worms as a way to tackle such diseases. 01:31-06:05: About Holoc…

1
Ipsen advances liver disease treatment 21:47

12M ago21:47

21:47

Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen. On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease. 00:56-00:49: Background information 01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver…

1
New class of small molecule therapeutics introduced 26:35

12M ago26:35

26:35

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience. 00:45-01:06: About Gate Bioscience 01:06-02:09: What are disease-causing extracellular proteins? 02:09-04:44: How have diseases caused by extracellular proteins been treated in the past? 04:4…

پادکست هایی که ارزش شنیدن دارند

پادکست های Labiotech

پادکست هایی که ارزش شنیدن دارند

راهنمای مرجع سریع